JNJ Latest Press Releases

-- July 23, 2026 --

TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma PRNewswire 8:30 AM

-- July 22, 2026 --

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA Robotic Surgical System Business Wire 7:00 AM

-- July 16, 2026 --

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award Business Wire 8:11 AM

DePuy Synthes Acquires Expanding Innovations Business Wire 8:00 AM

-- July 15, 2026 --

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026 Business Wire 6:25 AM

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook Business Wire 6:20 AM

-- July 8, 2026 --

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform Business Wire 7:45 AM

-- June 30, 2026 --

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity Globe Newswire 9:00 AM

-- June 26, 2026 --

Johnson & Johnson presents new IMAAVY (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis PRNewswire 12:35 PM

-- June 15, 2026 --

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida Business Wire 6:00 AM

-- June 13, 2026 --

New TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma PRNewswire 6:34 AM

-- June 11, 2026 --

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients Business Wire 7:45 AM

IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies PRNewswire 2:03 AM

-- June 10, 2026 --

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial Business Wire 11:22 AM

-- June 8, 2026 --

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform Business Wire 8:00 AM

-- June 3, 2026 --

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study PRNewswire 12:04 AM

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjgren's disease PRNewswire 12:03 AM

-- May 31, 2026 --

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited PRNewswire 8:30 AM

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm PRNewswire 8:28 AM

-- May 29, 2026 --

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer PRNewswire 2:00 PM

New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma PRNewswire 8:18 AM

-- May 28, 2026 --

FDA approves label expansion, cementing TREMFYA as the only IL-23 inhibitor proven to help stop further joint damage PRNewswire 7:11 PM

-- May 27, 2026 --

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results Business Wire 4:22 PM

-- May 14, 2026 --

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation PRNewswire 4:01 PM

-- May 13, 2026 --

CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research Globe Newswire 8:30 AM

-- May 12, 2026 --

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave C2 Aero Coronary IVL Catheter Business Wire 7:45 AM

-- May 11, 2026 --

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 4:34 PM

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP PRNewswire 8:00 AM

-- May 7, 2026 --

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission PRNewswire 8:00 AM

-- May 5, 2026 --

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease PRNewswire 8:05 AM

Johnson & Johnson study shows TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease PRNewswire 8:05 AM

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System Business Wire 7:00 AM

-- May 4, 2026 --

CAPLYTA (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis PRNewswire 8:00 AM

-- April 30, 2026 --

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations Business Wire 8:02 AM

-- April 27, 2026 --

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference Business Wire 4:33 PM

FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA) PRNewswire 8:03 AM

-- April 22, 2026 --

IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) PRNewswire 8:05 AM

-- April 21, 2026 --

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference Business Wire 4:22 PM

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026 Business Wire 7:45 AM

-- April 16, 2026 --

The Infrastructure Play Hiding in Plain Sight Across Cardiac Care Globe Newswire 11:00 AM

-- April 15, 2026 --

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference Business Wire 4:12 PM

-- April 14, 2026 --

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1% Business Wire 6:21 AM

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook Business Wire 6:20 AM

-- April 10, 2026 --

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision Business Wire 8:00 AM

-- April 9, 2026 --

Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value Globe Newswire 8:30 AM

-- April 7, 2026 --

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe Business Wire 8:00 AM

-- March 28, 2026 --

ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once-daily pill for plaque psoriasis PRNewswire 10:00 AM

-- March 18, 2026 --

FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide PRNewswire 7:49 AM

-- March 13, 2026 --

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer PRNewswire 12:36 PM

-- March 12, 2026 --

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients Business Wire 8:00 AM

-- March 5, 2026 --

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line PRNewswire 3:55 PM

-- March 3, 2026 --

/C O R R E C T I O N -- Johnson & Johnson/ PRNewswire 7:37 PM

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight PRNewswire 5:31 PM

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) PRNewswire 8:03 AM

-- March 2, 2026 --

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results Business Wire 4:30 PM

-- February 26, 2026 --

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer PRNewswire 2:30 PM

-- February 24, 2026 --

Johnson & Johnson seeks FDA approval of IMAAVY (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) PRNewswire 4:03 PM